Key result
Cardioband transcatheter annuloplasty reduces MR to ≤1+ in ~84% of patients.
Why the study?
Does the Cardioband transcatheter adjustable mitral annuloplasty system safely reduce mitral regurgitation severity in high-risk patients with functional mitral regurgitation?
Observational (n=45)
Yes
Does the Cardioband transcatheter adjustable mitral annuloplasty system safely reduce mitral regurgitation severity in high-risk patients with functional mitral regurgitation?
The Cardioband transcatheter direct mitral valve annuloplasty system is feasible and safe, providing effective and stable reduction in mitral regurgitation severity up to 12 months in high-risk patients with functional mitral regurgitation.
Name and manufacturer: The Cardioband System; Valtech Cardio Ltd., Or Yehuda, Israel (Figure 1A).Approval status: CE mark expected in
No takes yet. Share an insight, caveat, or question.
Maisano et al. (2015) conducted an observational in Functional mitral regurgitation (n=45). Cardioband transcatheter direct mitral valve annuloplasty system was evaluated on Intra-procedural mitral regurgitation reduction to ≤1+. The Cardioband transcatheter annuloplasty system was successfully implanted in 100% of patients, achieving intra-procedural mitral regurgitation reduction to ≤1+ in 84% of cases and a 20% reduction in septolateral diameter (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: